Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity
2 other identifiers
interventional
48
1 country
1
Brief Summary
The purpose of this study is to provide the first integrated examination of the interaction between muscle insulin action and exercise-stimulated muscle glucose uptake in obesity from the whole body to the cellular/molecular level.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Nov 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 27, 2020
CompletedFirst Posted
Study publicly available on registry
August 31, 2020
CompletedStudy Start
First participant enrolled
November 6, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 31, 2026
August 17, 2025
August 1, 2025
5.7 years
August 27, 2020
August 15, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Skeletal muscle glucose uptake
Is exercise induced skeletal muscle glucose uptake different in obese compared to lean adults
1 hour
Study Arms (2)
Lean
OTHERControl
Obese
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- For the exercise studies of leg glucose uptake - "insulin sensitive" group:
- Sedentary, normal weight, premenopausal women.
- Sedentary, age-matched normal weight men.
- Weight stable for two (2) months prior to study.
- Willing to provide written, informed consent.
- For the exercise studies of leg glucose uptake - "insulin resistant" group:
- For the exercise studies of leg glucose uptake - "insulin resistant" group:
- Upper body obese (UBO) premenopausal women.
- Age-matched upper body obese (UBO) men.
- Weight stable for two (2) months prior to study.
- Willing to provide written, informed consent.
You may not qualify if:
- Age \< 18 or \> 55 years (premenopausal women and age-matched men).
- Use of glucose-lowering agents.
- For female subjects: positive pregnancy test at the time of enrollment or study
- History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
- Active systemic illness or malignancy.
- Symptomatic macrovascular or microvascular disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael D Jensen, MD
Mayo Clinic
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 27, 2020
First Posted
August 31, 2020
Study Start
November 6, 2020
Primary Completion (Estimated)
July 31, 2026
Study Completion (Estimated)
July 31, 2026
Last Updated
August 17, 2025
Record last verified: 2025-08
Data Sharing
- IPD Sharing
- Will not share